Holen Sie sich die Stockscreener-App
474.72
2.25%
-10.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$485.06
Offen:
$478.05
24-Stunden-Volumen:
177.21K
Relative Volume:
0.45
Marktkapitalisierung:
$20.80B
Einnahmen:
$3.13B
Nettoeinkommen (Verlust:
$1.27B
KGV:
17.99
EPS:
26.3851
Netto-Cashflow:
$1.12B
1W Leistung:
-5.90%
1M Leistung:
-2.31%
6M Leistung:
+18.39%
1J Leistung:
+54.11%
1-Tages-Spanne:
$471.29
$484.73
1-Wochen-Bereich:
$471.29
$527.14
52-Wochen-Spanne:
$266.98
$537.19
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
474.51 | 21.26B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.84 | 56.11B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
120.44 | 51.60B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.24 | 46.00B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.05 | 36.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Ray Kurzweil Sells 4,910 Shares of United Therapeutics Corp - GuruFocus
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock - MarketBeat
United Therapeutics (UTHR) Receives Increased Price Target from UBS | UTHR Stock News - GuruFocus
UBS raises United Therapeutics stock price target to $705 on catalysts - Investing.com Canada
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate - ChartMill
AustralianSuper Pty Ltd Cuts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics pill shows late-stage success in rare lung disease PAH - IndiaMedToday
TD Cowen reiterates United Therapeutics stock Buy on ralinepag trial success - Investing.com India
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics CEO to give update at Leerink healthcare conference - Stock Titan
Leerink raises United Therapeutics stock price target on trial data By Investing.com - Investing.com South Africa
Jefferies raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
Jefferies raises United Therapeutics stock price target on trial data - Investing.com India
United Therapeutics Hits Day High with 13% Surge in Strong Intraday Performance - Markets Mojo
H.C. Wainwright reiterates Buy on United Therapeutics stock By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy on United Therapeutics stock - Investing.com
United Therapeutics (UTHR): Investor Outlook With A 13% Upside Potential - DirectorsTalk Interviews
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - marketscreener.com
United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening - Benzinga
United Therapeutics reports positive phase 3 trial for ralinepag By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Reports Positive Phase 3 Results for Ralinepag - GuruFocus
United Therapeutics reports positive phase 3 trial for ralinepag - Investing.com
United Therapeutics: Ralinepag cuts risk of clinical worsening by 55% in pivotal PAH trial - TradingView
Ralinepag cuts PAH clinical worsening by 55% in UTHR (NASDAQ: UTHR) phase 3 trial - Stock Titan
Once-daily PAH drug by United Therapeutics slows progressive disease - Stock Titan
United Therapeutics Corporation $UTHR Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600 - Finviz
United Therapeutics’ Stock Run Sets Up Big H1 2026 Trial Tests - Finimize
United Therapeutics Earnings Call Signals Growth Ahead - TipRanks
United Therapeutics Corp. Hits New 52-Week High at $537.11 - Markets Mojo
United Therapeutics Corporation (NASDAQ:UTHR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics Corp. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
H.C. Wainwright raises United Therapeutics stock price target to $600 - Investing.com Nigeria
United Therapeutics (NASDAQ:UTHR) Given New $600.00 Price Target at HC Wainwright - MarketBeat
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings - Benzinga
H.C. Wainwright raises United Therapeutics stock price target to $600 By Investing.com - Investing.com Australia
Why United Therapeutics (UTHR) Shares Are Sliding Today - Finviz
Oppenheimer Raises United Therapeutics (UTHR) Price Target to $6 - GuruFocus
Wells Fargo Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
UTHR: RBC Capital Raises Price Target for United Therapeutics | - GuruFocus
Wells Fargo & Company Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price - MarketBeat
UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance - Finviz
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2025 Earnings Call Transcript - Insider Monkey
MANNKIND CORP SEC 10-K Report - TradingView
United Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Mar 05 '26 |
Sale |
483.16 |
8,300 |
4,010,187 |
36,844 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 04 '26 |
Sale |
489.91 |
9,500 |
4,654,129 |
130 |
| KURZWEIL RAY | Director |
Mar 04 '26 |
Option Exercise |
101.80 |
4,910 |
499,838 |
17,580 |
| KURZWEIL RAY | Director |
Mar 04 '26 |
Sale |
489.02 |
4,910 |
2,401,088 |
12,670 |
| Thompson Tommy G | Director |
Mar 04 '26 |
Option Exercise |
101.80 |
2,000 |
203,600 |
10,480 |
| Thompson Tommy G | Director |
Mar 04 '26 |
Sale |
489.42 |
2,000 |
978,839 |
8,480 |
| CAUSEY CHRISTOPHER | Director |
Mar 04 '26 |
Option Exercise |
119.76 |
20 |
2,395 |
4,210 |
| CAUSEY CHRISTOPHER | Director |
Mar 04 '26 |
Sale |
490.17 |
20 |
9,803 |
4,190 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 03 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
9,630 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 03 '26 |
Sale |
499.42 |
9,500 |
4,744,467 |
130 |
2.63%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):